Registered business in FR. Official registry identity, filed financial evidence and a rounded indicative valuation range on one indexed company profile.
Historical rounded range based on the latest available public filing for fiscal year 2016. This is not a current market value or asking price.
Based on filed company accountsCreate a free account to see the detailed curve, the factors that influence it, and an indicative five-year outlook.
Free account · private workspace
Each step adds evidence that narrows the range. Public filings are a starting point. Connected accounts, owner context and method review make the valuation more useful for real decisions.
Continue privately and connect your accounting data to make the graph more accurate.
Continue as ownerTrack the buying status below. If the owner opens a process, you can request a conversation and review the details before making an offer.
View buying statusYou have seen the historical curve. Create a free account to explore a private five-year value scenario and the assumptions behind it.
The historical indicative range for HEPARTEX uses the latest available public filing and sector calibration. It is not a current market value or asking price; current owner or advisor data is needed for a full valuation.
This company is not currently listed for sale on Upswitch.
This is an estimate, not an asking price. It is based on dated public sources and is not an owner forecast, offer, investment advice, or confirmation that the company is for sale.
Request verified control to add current figures, improve the profile and manage what happens next. We verify ownership before granting access.
HEPARTEX is a business in NACE sector 46.75 based in France. The company was founded in 1900, incorporated as a 5710.
HEPARTEX is listed in French National Business Register (RNE/INPI) under registry number 309694065. The public employee band is 02, a useful triage field for banks, credit analysts, and M&A acquirers. This profile consolidates official annual accounts into one indexable company dossier.
Within the French NACE 46.75 cluster, public-record data is filed annually via the national company registry.
Across the 2015-2016 window revenue has stayed broadly flat, moving from €30,187,585 to €30,330,638.
The most recent annual filing covers 2016 (period end 2016-12-31).
If you are researching HEPARTEX for acquisition, investment, or due-diligence purposes, this page consolidates its firmographics, multi-year filings, and a historical indicative range based on the latest available public filing, not a current market value.
Public regulator-filed figures across 2 years.
Fiscal year | Revenue | EBITDA | Total assets | Equity | Filing |
|---|---|---|---|---|---|
| 201631 Dec 2016 | €30,330,638 | - | €21,424,025 | €14,984,540 | - |
| 201531 Dec 2015 | €30,187,585 | - | €17,417,421 | €13,270,064 | - |
HEPARTEX was founded in 1900 and is registered with French National Business Register (RNE/INPI), incorporated as a 5710.
HEPARTEX is registered under NACE 46.75: NACE 46.75. That places the business within the French cluster for this activity.
The most recently filed annual accounts cover fiscal year 2016 (period end 2016-12-31), publicly available via French National Business Register (RNE/INPI).
This page shows a rounded historical indicative range for HEPARTEX, based on the latest available public filing for fiscal year 2016. It is not a current market value, asking price, certified or statutory valuation, or financial, investment, tax or legal advice. Verify current figures before relying on it for any decision or transaction.
Company identity and public facts are reused from the official or licensed source named on this page, with its filing or update date. Upswitch estimates remain distinct from source facts and do not imply endorsement by the registry. Natural-person enterprises are excluded from public valuation pages, and public registry personal data is not used for direct marketing.
Connected to this company and want something corrected? Request a correction or removal · Privacy policy · Terms & conditions · Data sources & evidence
